Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Stud

Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after

Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday&#39

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday'

Building on promising preclinical and clinical data, this collaboration intends to refine patient id

Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validat

Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Te

Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecent

The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Arou

https://www.sec.gov/Archives/edgar/data/1595248/000143774926019760/gnpx20260518_s3.htm

Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Surviv

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene the

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Te

Genprex (NASDAQ:GNPX) reported quarterly losses of $(0.64) per share. This is a 95.08 percent increa

The health care sector has oversold stocks with RSI below 30, presenting an opportunity for traders

Strengthens Patent Estate and Expands Protection in Another Target MarketAUSTIN, Texas, April 30, 20

Strengthens Patent Estate and Expands Protection in Another Target Market AUSTIN, Texas, April 30, 2

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Te

AUSTIN, Texas, April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GN

Research on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentia

TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene TherapyREQORSA Induced Apopt

TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy REQORSA Induced Apop

Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report)

A Congress member continues to buy small cap stocks. Here's the latest names added to his invest

Genprex (NASDAQ: GNPX - Get Free Report) will likely be issuing its resultson Friday, March 27th. An

Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene Therap

AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GN

A member of Congress is buying stock in two small cap companies in 2026. Here's the stocks and w

Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.&

Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'

Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentr

A Republican U.S. Representative made multiple trades in 2025, including Cracker Barrel and a little

A Republican U.S. Representative made multiple trades in 2025, including Cracker Barrel and a little

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and S

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and S

Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy i

Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy i

The list of the top 10 members of Congress for 2025 investment portfolio gains. Where did Marjorie T

A congressman bought shares of a small cap company recently. Here's a look at the stock and why

 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene the

 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene the